R-GNOSIS is coordinated by Marc Bonten (UMC Utrecht) and brings together a multidisciplinary team with complementary expertise of clinicians, microbiologists and epidemiologists, infectious disease specialists, caregivers in inpatient care and mathematical modellers. The R-GNOSIS consortium is made of 19 partners from 9 countries which include United Kingdom, Denmark, Germany, Netherlands, Belgium, France, Spain, Switzerland and Israel.
Da Volterra is a French biotechnology company located in Paris (France). It is committed to the development of a portfolio of unique products in the antibacterial field, with a specific focus on Clostridium difficile and antibiotic resistance. Da Volterra has developed innovative strategies to protect the gut flora from antibiotic alteration and contain resistance by limiting the dissemination of resistant organisms from the gut flora.
Da Volterra aims at preventing the emergence of resistance and nosocomial infections by multidrug resistant bacteria, thanks to a fine understanding of the mechanisms of bacterial resistance, together with a well-validated drug delivery and drug development expertise. Recently, research efforts have been directed towards intestinal specific drug delivery, with 10 families of patents already filed. To assess the efficacy of its drug candidates, Da Volterra has developed its own in vitro and in vivo preclinical models and validated its products’ proof of concept.
Florence Séjourné - Chief Executive OfficerFlorence Séjourné joined Da Volterra as CEO in the summer of 2008. Graduated from the “Ecole des Mines de Paris” and from UofIChicago in Pharmaceutical Sciences, she joined a bioincubator assisting biotech start-up entrepreneurs, before co-founding Genfit, one of the leading public European biotech co. in the metabolic diseases field, where she was COO, VP Business Development, Alliance manager and Member of the Board from 1999 to 2008. Florence Séjourné therefore brings to Da Volterra the experience of successful entrepreneurial adventures, including the capacity to set up and lead a highly professional R&D organization, to raise private and public funds, and to structure and negotiate deals with Pharmaceutical and Biotech Companies in a highly competitive international environment.